B

Bimeda

Develops medicines and vaccines for animals

Production Manager

Full-TimeUpdated on 10/21/2026
No salary listed
Senior
Bachelor's
Le Sueur, MN, USA
In Person
Manufacturing & Production Operations

About the job

Requirements
  • At least 5 years of pharmaceutical or nutraceutical manufacturing experience, including 3 years of leadership experience directly within solid-dose or powder drug product manufacturing, such as blending, milling, tablet compression, coating, and/or packaging.
  • A bachelor's degree in Business Management, Engineering, Chemistry, or an equivalent life science field, or significant direct and relevant experience.
  • Ability to work in fast-paced environments in a leadership capacity and facilitate objective decision-making.
  • Ability to perform departmental capacity analysis and recommend short- and long-term strategies.
  • Demonstrated leadership and vision in managing staff groups and major projects or initiatives.
  • Demonstrated commitment to high professional ethical standards and a diverse workplace.
  • Strong people-management skills.
  • Strong command of written and verbal English.
Responsibilities
  • Translate company strategy into meaningful plans and actions at the operations level.
  • Manage and evaluate daily, weekly, and monthly key performance indicator information to identify bottlenecks, execute problem-solving actions, and remove obstacles to ensure smooth production flow.
  • Participate in budget planning, manage the production budget, and pursue cost management and improvements.
  • Maintain effective communication with internal and external customers.
  • Observe and align operations across departments to understand methods, procedures, and standards related to departmental duties.
  • Identify production needs and execute actions involving process management, staffing, equipment, and training.
  • Prioritize continuous improvement in the day-to-day production system and management.
  • Build and sustain employee trust through active listening, understanding, coaching, and support.
  • Assess existing talent to determine whether skills and competencies fit current roles and future goals.
  • Set performance goals and objectives with direct reports.
  • Ensure standard operating procedure, safety, and current good manufacturing practice training is current and employees comply.
  • Develop employees through daily learning, training, workshops, and mentorship.
  • Plan, direct, and coordinate powder and tablet production and related services to produce quality, compliant products safely and economically while meeting on-time customer demand.
  • Identify trends in processing times for blending, milling, compression, coating, filling, and packaging, and take appropriate action to improve operating conditions.
  • Provide technical guidance to staff and colleagues, anticipate business needs, identify solutions, and approve technical documentation such as investigations, protocols, qualification, and validation documents as required.
  • Interface with external organizations including the Food and Drug Administration, Drug Enforcement Administration, contract auditors, the Occupational Safety and Health Administration, and the Environmental Protection Agency to ensure compliance with current regulations.
  • Set and measure team performance and goals, contribute to production scheduling decisions, work cross-functionally to close deviation investigations, and introduce new product stock-keeping units.
  • Take a hands-on approach to solving production constraints and improving production capacity, and oversee day-to-day activities in the Water Soluble Powders and Tablets building.
  • Lead and support modifications and upgrades to powder handling, blending, tablet press, coating, and packaging equipment to improve automation and efficiency, meet regulatory requirements, and replace obsolete equipment, controls, and systems.
  • Improve production department management and operational skills, and provide technical advice to organizational departments on powder blending, compression, coating, filling, and packaging equipment improvements based on departmental systems.
  • Manage Powder Blending and Filling, and Tablet Compression, Coating, and Packaging production lines and departments for non-sterile, water-soluble powders and tablets.
  • Apply cost-accounting principles in a manufacturing environment, develop cost-reduction plans, and ensure departments operate within budget.
  • Ensure current good manufacturing practice compliance and achievement of performance, safety, quality, delivery, and cost targets.
  • Support continuous-improvement project teams by providing adequate time for process-improvement activities.
  • Encourage and mentor continuous-improvement leaders to educate and empower a continuous-improvement mindset throughout production operations.
  • Model and establish a continuous-improvement culture on the manufacturing floor.
Desired Qualifications
  • A degree in Manufacturing Technology, Engineering, or a related field.
  • Two to three years of continuous-improvement experience; Green Belt or Black Belt certification is a plus.
  • Prior experience with water-soluble powder and/or tablet manufacturing equipment, such as ribbon blenders, fluid bed processors, tablet presses, and coating pans.

About the company

Bimeda develops and manufactures veterinary medicines and vaccines for veterinarians, farmers and animal health distributors around the world. Its portfolio covers parasite control and infections, alongside pain relief, reproductive health and nutritional supplements for livestock, horses and companion animals. The company makes injections, oral pastes, powders and tablets in its own plants, with formulations and approved uses tailored to each market. It earns revenue by selling Bimeda-branded products and by manufacturing private-label medicines for other animal health companies. Founded in Ireland in 1960, Bimeda has its global headquarters in Dublin, Ireland.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

N/A

Founded

1960

Get referred to Bimeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Bimeda gained U.S. equine market access: its first approved GastroGard generic launched nationwide in May 2026.
  • U.S. capacity broadens: by May 2026, Bimeda had bought selected manufacturing assets at Dechra's Pomona facility.
  • Bimeda advertises development support in the UK: education funding accompanies 24 starting annual-leave days plus public holidays.

What critics are saying

  • Bimeda's screwworm indication is temporary: its August 2026 Bimectin authorization ends with the emergency declaration or revocation.
  • Bimeda faces an older ulcer brand: FDA's April 2026 review names GastroGard, approved in 1999, as Gastrobim's reference.
  • Factory schedules include nights: Bimeda's September 2026 Le Sueur technician posting lists 9pm-5:30am shifts at $24/hour.

What makes Bimeda unique

  • Bimeda's cattle supplements use dissolving glass: Cosecure releases minerals steadily for up to six months.
  • Bimeda's fish health division designs vaccination plans: AquaTactics combines veterinary consultation with pathology and custom prescription vaccination protocols.
  • Bimeda's laboratory business serves other drugmakers: its Rainbowlabs joint venture tests batches and audits manufacturing quality.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Paid Vacation
  • Life Insurance
  • Employee Assistance Program
  • Paid Holidays

Company News

British Veterinary Association
Aug 4th, 2026
New treatment for bovine endometritis.

New treatment for bovine endometritis. 4 Aug 2026 11:00 AM Bimeda UK has launched Bimacure, which it says is the UK's first generic intrauterine cefapirin suspension for cattle, for the treatment of subacute and chronic endometritis. The formulation contains 500mg cefapirin per syringe and is for use in cows at least 14 days after parturition. It is supplied in packs of 10 sets each of syringes, administration catheters and gloves; the catheter and syringe connection have been designed to avoid 'pop offs' at critical moments. The firm says feedback about the product from other markets has been "extremely positive".

Feedstuffs
May 19th, 2026
Bimeda introduces enhanced BOVitalize Plus.

Bimeda introduces enhanced BOVitalize Plus. Product now fortified with A. oryzae to support cattle health, digestion and performance. May 19, 2026 Bimeda is proud to announce the launch of its newly enhanced BOVitalize Plus, now fortified with Aspergillus oryzae to deliver an even more comprehensive approach to cattle health, digestion and performance. This advancement builds on the trusted formulation of essential trace minerals and vitamins - selenium, copper, zinc, vitamin A and vitamin E - by adding targeted digestive support designed to help cattle get more from every bite of feed. For producers and veterinarians, the inclusion of A. oryzae represents a significant step forward in rumen efficiency. A oryzae provides enzymatic activity that enhances fiber breakdown, helping cattle maintain intake and digestive consistency during diet transitions, periods of stress or when forage quality declines. By supporting more efficient fiber utilization, the upgraded BOVitalize Plus helps optimize nutrient absorption, stabilize the rumen environment, and promote improved overall performance across all stages of production. This enhancement reflects its commitment to delivering solutions that truly support the challenges cattle face every day," said Dr. Eric Moore, head of technical services North America at Bimeda. "By combining key vitamins and minerals with the proven digestive benefits of Aspergillus oryzae - and refining how the formula performs in suspension - we're offering a more complete, performance-driven supplement designed to keep animals healthy, efficient and moving forward." The improved BOVitalize Plus continues to offer the same convenient oral dosing, eliminating the need for additional injections and reducing labor at the chute. With the added digestive benefits of A. oryzae, the product now delivers an even stronger value proposition for both cow-calf and stocker operations seeking to improve health, consistency and overall productivity. BOVitalize Plus is now available through authorized Bimeda distributors. Bimeda is a leading global manufacturer of animal health products used in more than 80 countries worldwide and is committed to providing innovative solutions that support livestock health, welfare and performance. Feedstuffs is the news source for animal agriculture

The Horse
May 6th, 2026
Bimeda(r) announces U.S. Availability of gastrobim(tm)(omeprazole) the first and only fda-approved bioequivalent to gastrogard(r)(omeprazole) for Equine Gastric Ulcer treatment.

Bimeda(r) announces U.S. Availability of gastrobim(tm)(omeprazole) the first and only fda-approved bioequivalent to gastrogard(r)(omeprazole) for Equine Gastric Ulcer treatment. Now available nationwide. Horse owners are encouraged to contact their veterinarian. Bimeda(R), a global leader in animal health solutions, today announced the U.S. launch of GASTROBIM(TM)(omeprazole), the first and only FDA-approved bioequivalent to GastroGard(R)(omeprazole) for the treatment and prevention of recurrence of gastric ulcers in horses and foals four weeks of age and older. This apple-flavored formulation offers veterinarians, trainers, and horse owners a clinically equivalent, high-quality alternative for the effective management of Equine Gastric Ulcer Syndrome (EGUS), addressing a critical need in equine health. Since its initial launch in 2024, GASTROBIM(TM) has rapidly emerged as the fastest-growing omeprazole product in Canada and Europe. Its strong adoption and positive reception among veterinarians and horse owners underscore its proven efficacy in treating and healing gastric ulcers, reinforcing its position as a trusted therapeutic option worldwide. The introduction of GASTROBIM(TM) in the U.S. further expands Bimeda's established equine portfolio, which includes leading brands such as EquiMAX(R)(1.87% ivermectin 14.03% praziquantel), Polyglycan(TM)(hyaluronic acid + chondroitin sulfates C4 & C6 + N-acetyl-D-glucosamine sterile solution), Detomequin(R)(detomidine hydrochloride), and Bimectin(R)(ivermectin paste), and reflects the company's ongoing commitment to delivering innovative, reliable solutions to the equine industry. "We are thrilled to introduce GASTROBIM(TM) to the U.S. market," said Eric Moore, DVM, Bimeda's Head of Technical Services North America. "Gastric ulcers remain one of the most common and performance limiting conditions in horses. Offering a bioequivalent, rigorously tested treatment underscores our commitment to supporting equine health, welfare, and performance at an affordable price." Equine Gastric Ulcer Syndrome (EGUS) affects a significant percentage of performance horses, often leading to reduced appetite, behavioral changes, discomfort, and decreased athletic performance. By introducing a bioequivalent, apple-flavored alternative, Bimeda aims to broaden access to effective treatment options and support improved health and performance outcomes across the equine industry.

American Association of Swine Veterinarians
Apr 15th, 2026
People on the move: dr. Chris Olsen.

People on the move: dr. Chris Olsen. Dr. Chris Olsen has joined Bimeda as their U.S. Swine Technical Service Veterinarian. In this role, he will support the growth of the company's swine autogenous vaccine business and provide technical expertise across its swine pharmaceutical portfolio. He was previously employed by Pharmacosmos. Dr. Olsen's updated contact information is available at aasv.org/directory. Are you on the move? Let Aasv Go know at [email protected].